重组人促红细胞生成素治疗维持性血液透析肝病患者肾性贫血的疗效观察  

Effect of r Hu EPO treatment on renal anemia in maintenance hemodialysis patients with liver disease

作　　者：孙培荣[1] 马列清[1] 刘凯燕[1] 李德新[1] 王凡[1] 刘静[1] 

机构地区：[1]首都医科大学附属北京佑安医院泌尿中心,乙型肝炎与肝癌转化医学研究北京市重点实验室,北京100069

出　　处：《临床药物治疗杂志》2015年第3期80-82,共3页Clinical Medication Journal

基　　金：卫生部重大传染病专项资助项目(20082X10002-026)

摘　　要：目的:观察重组人促红细胞生成素(r Hu EPO,促红素EPO)治疗维持性血液透析肝病患者肾性贫血的疗效。方法:收集2014年6―12月北京佑安医院血液净化中心维持性血液透析肝病患者68例,透析结束时皮下注射促红素,根据血红蛋白结果调整剂量,观察6个月内血红蛋白达标情况。每3月化验一次血红蛋白(HB)、红细胞压积(HCT)、血清铁(FE)、血清铁蛋白(FER)、转铁蛋白饱和度(TS)、白蛋白(ALB)、甲状旁腺激素(PTH)、尿素氮(BUN)。数据采用SPSS统计分析,所有计量资料采用·x±s表示,组间比较用t检验。结果:使用促红素治疗3个月及6个月,血红蛋白分别和治疗前比较,差异均有显著性(P<0.05),血红蛋白达标率64.71%;治疗6个月较治疗3个月血红蛋白水平比较,差异有显著性(P<0.05)。尿素氮清除率、甲状旁腺激素、血清铁、血清铁蛋白、转铁蛋白饱和度方面,3个月较0月比较,6个月较3个月比较,差异均无显著性。结论:促红素可以改善维持性血液透析肝病患者肾性贫血,提高患者的生存期和生活质量。Objective： To investigate the effect of rHuEPO treatment on renal anemia in continuous hemodialysis patients with liver disease. Methods： 68 continuous hemodialysis patients with liver disease were included from June. to December. 2014. EPO was administrated when dialysis ends. Doses were adjusted based on the level of hemoglobin. Hemoglobin （HB）, hematocrit （HCT）, iron （FE）, serum ferritin（FER）, transferrin saturation （TS）, albumin （ALB）, parathyroid hormone （PTH）urea nitrogen （BUN） were checked every three month. Data were statistical analyzed, by SPSS. Data were presented in x^-±s. Groups were compared by t test. Results： There were significant difference in HbG （Hct） level between before and after 3 or 6 months treatment. Stand and rate of HbG was 64.71%. After 6 months treatment with EPO. No significant difference were seen in Kt · v^-1, PTH,TE,TERR and TS level between before and after 3 or 6 months treatment. Conclusion： EPO therapy canimprove renal Anemia and life＇s quality in maintenance hemodia!ysis patients with liver disease.

关 键 词：促红细胞生成素 维持性血液透析 肝病 肾性贫血 

分 类 号：R978.7[医药卫生—药品] R512.62[医药卫生—药学]